If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHikma Pharmaceuticals Regulatory News (HIK)

Share Price Information for Hikma Pharmaceuticals (HIK)

Share Price is delayed by 15 minutes
Get Live Data
1,548.00    -6.00 (-0.39%)
Bid:
1,544.00
Ask:
1,547.00
Spread: 3.00 (0.194%)
Market Cap: £3.26b
HIK Live PriceLast checked at - London Stock Exchange

Intraday Hikma Pharmaceuticals Share Chart

LTIP Awards

30 Apr 2008 15:22

Hikma Pharmaceuticals Plc30 April 2008 Hikma Pharmaceuticals PLC - LTIP Awards LONDON, 30 April 2008: Hikma Pharmaceuticals PLC (LSE: HIK) (DIFX: HIK)announces that the Remuneration Committee has made the following nil-cost awardsunder the Hikma Pharmaceuticals PLC 2005 Long-Term Incentive Plan (the "LTIP")to Directors and Persons Discharging Managerial Responsibility ("PDMRs") of theCompany. Awards under the LTIP were made on 29 April 2008 at a price of £4.64 perordinary share as follows:- Name of Director/PDMR Number of LTIP SharesSaid Darwazah 90,000Mazen Darwazah 54,000Bassam Kanaan 54,000Taghreed Al-Shunnar 54,000Majda Labadi 54,000Nabil Rizk 54,000 The shares subject to the LTIP awards will only be released to the participantsin three years time, subject to their continued employment and the satisfactionof the comparative Total Shareholder Return ("TSR") performance target.Participants will only receive the full benefit of their share incentives if TSRperformance against the Comparator Group is at least at the upper quartile. - ENDS -Enquiries: Hikma Pharmaceuticals PLCHenry Knowles +44 20 7399 2760Company Secretary Susan Ringdal +44 20 7399 2760Investor Relations Director About Hikma Hikma Pharmaceuticals PLC is a fast growing multinational group focused ondeveloping, manufacturing and marketing a broad range of both branded andnon-branded generic and in-licensed pharmaceutical products. Hikma's operationsare conducted through three businesses: "Branded", "Injectables" and"Generics". Hikma's operations are based principally in the Middle East andNorth Africa ("MENA") region, where it is a market leader and sells across 17countries, the United States and Europe. In 2007, the Group achieved revenuesof $449 million (2006 $317 million) and profit attributable to shareholders was$63 million (2006 $55 million). For news and other information, please visitwww.hikma.com. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
5th Oct 20179:49 amRNSBlock listing Interim Review
2nd Oct 20173:36 pmRNSTotal Voting Rights
28th Sep 20173:29 pmRNSHolding(s) in Company
25th Sep 201711:27 amRNSHolding(s) in Company
14th Sep 20173:52 pmRNSHolding(s) in Company
25th Aug 20178:41 amRNSHolding(s) in Company
17th Aug 20177:00 amRNSHikma announces licensing agreement with Takeda
17th Aug 20177:00 amRNSHalf-year Report
10th Aug 201710:05 amRNSDirector/PDMR Shareholding
10th Aug 201710:02 amRNSDirector/PDMR Shareholding
9th Aug 20179:54 amRNSDirector/PDMR Shareholding
4th Aug 20179:56 amRNSHolding(s) in Company
3rd Aug 20172:22 pmRNSNotice of Results
24th Jul 201710:53 amRNSHolding(s) in Company
4th Jul 201711:02 amRNSTotal Voting Rights
3rd Jul 20173:03 pmRNSHolding(s) in Company
30th Jun 20174:11 pmRNSHolding(s) in Company
26th Jun 20177:00 amRNSLeadership and Structural Changes to US Business
12th Jun 20174:31 pmRNSDirector/PDMR Shareholding
2nd Jun 20174:51 pmRNSTotal Voting Rights
31st May 20179:38 amRNSDirector/PDMR Shareholding
19th May 20172:44 pmRNSResult of AGM
19th May 20177:00 amRNSTrading Statement
15th May 20173:30 pmRNSDirector/PDMR Shareholding
11th May 20177:50 amRNSHikma update on ANDA for generic Advair Diskus
8th May 20179:23 amRNSChange of Registered Address
3rd May 20175:23 pmRNSTotal Voting Rights
3rd May 201710:37 amRNSChange of Registered Office
28th Apr 20172:30 pmRNSDirector/PDMR Shareholding
28th Apr 20171:57 pmRNSDirector/PDMR Shareholding
24th Apr 20173:35 pmRNSDirector/PDMR Shareholding
13th Apr 20178:58 amRNSDirector/PDMR Shareholding
13th Apr 20178:43 amRNSDirector/PDMR Shareholding
13th Apr 20178:42 amRNSDirector/PDMR Shareholding
13th Apr 20178:41 amRNSDirector/PDMR Shareholding
13th Apr 20178:36 amRNSDirector/PDMR Shareholding
11th Apr 20174:01 pmRNSDirector/PDMR Shareholding
7th Apr 201711:55 amRNSAnnual Financial Report
6th Apr 20177:00 amRNSHikma enters into settlement agreement with Jazz
3rd Apr 20173:59 pmRNSTotal Voting Rights
3rd Apr 20173:56 pmRNSBlock listing Interim Review
27th Mar 201711:13 amRNSHolding(s) in Company
23rd Mar 20179:30 amRNSDirector/PDMR Shareholding
15th Mar 20177:00 amRNSFinal Results
10th Mar 20177:30 amRNSHikma launches Desvenlafaxine Succinate Tablets
8th Mar 20174:01 pmRNSNotice of Results
8th Mar 20171:30 pmRNSDirector/PDMR Shareholding
1st Mar 20172:38 pmRNSTotal Voting Rights
13th Feb 20179:19 amRNSLicensing agreement with Orion for Easyhaler®
6th Feb 20172:27 pmRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.